Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for EGFR-Mutated Non–Small-Cell Lung Cancer: Regulatory Considerations

Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

(2022) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

(2022) Alissa J. Cooper et al.   Nature Reviews Clinical Oncology

Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)

(2022) Giulio Metro et al.   Journal of Thoracic Disease

LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study

(2022) J. Mazieres et al.   ANNALS OF ONCOLOGY

New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer

(2022) Nicolas Girard   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Evaluating Cancer Drugs in Patients With Central Nervous System Metastases

(2021) Shanthi Marur et al.   JAMA Oncology

Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report

(2021) Zhao-Jie Han et al.   Annals of Palliative Medicine

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer

(2021) Pınar Özden Eser et al.   Science Translational Medicine

Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review

(2020) Andrew J. Piper-Vallillo et al.   JOURNAL OF CLINICAL ONCOLOGY

Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer

(2019) Eiki Ichihara et al.   LUNG CANCER

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient

(2018) Giulio Metro et al.   CLINICAL DRUG INVESTIGATION

Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.

(2018) Zofia Piotrowska et al.   Cancer Discovery

Combination Osimertinib and Gefitinib in C797S and T790M EGFR- Mutated Non–Small Cell Lung Cancer

(2017) Surein Arulananda et al.   Journal of Thoracic Oncology

Response assessment criteria for brain metastases: proposal from the RANO group

(2015) Nancy U Lin et al.   LANCET ONCOLOGY